Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label Study to Evaluate Ovarian Follicular Activity and Hormone Levels With the Oral Contraceptive Regimen DR-102 Compared to Two 28-day Oral Contraceptive Regimens Containing Different Synthetic Progestins
Conditions
Interventions
Desogestrel/ethinyl estradiol and ethinyl estradiol
28-day drospirenone oral contraceptive
+1 more
Locations
2
United States
Teva Investigational Site 10119
Philadelphia, Pennsylvania, United States
Teva Investigational Site 10118
Seattle, Washington, United States
Start Date
January 31, 2011
Primary Completion Date
March 31, 2012
Completion Date
March 31, 2012
Last Updated
December 8, 2021
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions